Delivery Order SPE2DB24D2216-SPE2DB25FGPHW
- Not listed
- The Defense Logistics Agency awarded a $41,480.93 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Rexulti 1 mg tablets (30-count units). This firm fixed-price, competitively awarded contract with an ultimate completion date of July 29, 2025, represents a child order under AmerisourceBergen's larger pharmaceutical supply vehicle with the DLA. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Rexulti 1 mg tablets in a 30-count package, with a contract ceiling value of $4,260.21. This non-set-aside, competitively awarded delivery order represents a firm fixed price transaction and is scheduled for completion by August 15, 2025. The work will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $46,854.75 to AmerisourceBergen Drug Corp for the supply of Rexulti 2 mg tablets (30-count units) under a firm fixed-price contract type. The award was made on August 5, 2025, with an ultimate completion date of August 6, 2025, and represents a non-competitive set-aside delivery order. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement...
- The Defense Logistics Agency awarded a delivery order valued at $4,508.41 to AmerisourceBergen Drug Corp for the supply of Rexulti 1 mg tablets (30-count package) on August 18, 2025, with an ultimate completion date of August 19, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and represents a small-value transaction within the company's extensive pharmaceutical distribution portfolio for federal medical procurement. The product will be...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Rexulti 1 mg tablets (30-count) on August 13, 2025, with a ceiling value of $1,002.23 and firm fixed pricing. This delivery order is non-set-aside and represents a competitive award to the pharmaceutical distributor, with an ultimate completion date of August 14, 2025. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Rexulti 0.5 mg tablets (30-count) with a ceiling value of $1,952.46. This is a firm fixed price delivery order with no set-aside designation, issued under a competitive process. The contract is due for completion by August 11, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This award represents a child order under the company's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Rexulti 2 mg tablets in a quantity of 30 units, with a ceiling value of $9,482.33. This is a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. The contract is scheduled for ultimate completion on August 1, 2025, and the place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Rexulti 1 mg tablets (30-count packages) under a firm fixed-price contract valued at $5,508.44, with an ultimate completion date of July 25, 2025. This non-set-aside competitive award represents a single delivery order for a pharmaceutical product commonly prescribed for psychiatric conditions. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $35,464.57 to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Rexulti 0.5 mg tablets in quantities of 30. This firm fixed price delivery order, with an ultimate completion date of July 25, 2025, represents a pharmaceutical supply transaction supporting federal medical procurement needs. The award was competitively awarded with no set-aside designation. Performance will be executed from AmerisourceBergen's corporate...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $15,697.80 to AmerisourceBergen Drug Corp for the supply of Rexulti 1 mg tablets (30-count units) on August 13, 2025, with an ultimate completion date of August 14, 2025. This firm fixed-price, non-set-aside contract represents a single delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999 billion vehicle extending through December 2026....
- SPE2DB24D2216Indefinite Delivery Contract
- SPE2DB24D2216-SPE2DB25FGPHWDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $30,339.39 to AmerisourceBergen Drug Corp for the supply of Rexulti 1 mg tablets (30-count units) under a firm fixed price arrangement. The award, issued on July 29, 2025, with an ultimate completion date of July 30, 2025, represents a non-competitive delivery order placed against AmerisourceBergen's larger contract vehicle. Performance will be executed at the contractor's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters as a major pharmaceutical distributor serving federal healthcare procurement needs. This delivery order falls under AmerisourceBergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive pharmaceutical support vehicle that remains active through December 2026. The parent IDC enables AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs globally, serving customers including the Defense Health Agency and U.S. Coast Guard. Rexulti, an atypical antipsychotic medication, represents one of the specialized pharmaceutical products routinely procured through this vehicle to support federal medical supply requirements across the defense healthcare system.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $30.3k | 7/29/25 |